当前位置: X-MOL 学术Ann. Review Paleopathol. Mech. Disease › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
Annual Review of Pathology: Mechanisms of Disease ( IF 36.2 ) Pub Date : 2017-01-30 00:00:00 , DOI: 10.1146/annurev-pathol-052016-100304
Jonathan H Esensten 1 , Jeffrey A Bluestone 2 , Wendell A Lim 3
Affiliation  

Engineered T cells are currently in clinical trials to treat patients with cancer, solid organ transplants, and autoimmune diseases. However, the field is still in its infancy. The design, and manufacturing, of T cell therapies is not standardized and is performed mostly in academic settings by competing groups. Reliable methods to define dose and pharmacokinetics of T cell therapies need to be developed. As of mid-2016, there are no US Food and Drug Administration (FDA)–approved T cell therapeutics on the market, and FDA regulations are only slowly adapting to the new technologies. Further development of engineered T cell therapies requires advances in immunology, synthetic biology, manufacturing processes, and government regulation. In this review, we outline some of these challenges and discuss the contributions that pathologists can make to this emerging field.

中文翻译:


工程治疗性 T 细胞:从合成生物学到临床试验

工程化 T 细胞目前正在进行临床试验,用于治疗癌症、实体器官移植和自身免疫性疾病患者。然而,该领域仍处于起步阶段。T 细胞疗法的设计和制造没有标准化,主要由竞争团体在学术环境中进行。需要开发可靠的方法来定义 T 细胞疗法的剂量和药代动力学。截至 2016 年年中,市场上还没有美国食品和药物管理局 (FDA) 批准的 T 细胞疗法,FDA 法规只是在慢慢适应新技术。工程化 T 细胞疗法的进一步发展需要在免疫学、合成生物学、制造工艺和政府监管方面取得进展。在本次审查中,

更新日期:2017-01-30
down
wechat
bug